nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ALB—focal segmental glomerulosclerosis	0.464	1	CbGaD
Naloxone—SLCO1A2—Cyclosporine—focal segmental glomerulosclerosis	0.205	0.546	CbGbCtD
Naloxone—CYP2C8—Cyclosporine—focal segmental glomerulosclerosis	0.082	0.218	CbGbCtD
Naloxone—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.0555	0.148	CbGbCtD
Naloxone—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0332	0.0884	CbGbCtD
Naloxone—CREB1—Developmental Biology—TRPC6—focal segmental glomerulosclerosis	0.000167	0.00105	CbGpPWpGaD
Naloxone—ESR1—AP-1 transcription factor network—MMP9—focal segmental glomerulosclerosis	0.000166	0.00104	CbGpPWpGaD
Naloxone—OPRD1—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	0.000162	0.00102	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000161	0.00101	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—CD40LG—focal segmental glomerulosclerosis	0.000161	0.00101	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000159	0.000998	CbGpPWpGaD
Naloxone—OPRM1—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.000159	0.000994	CbGpPWpGaD
Naloxone—TLR4—Immune System—CD40LG—focal segmental glomerulosclerosis	0.000158	0.000988	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000156	0.000974	CbGpPWpGaD
Naloxone—CREB1—Immune System—PIAS1—focal segmental glomerulosclerosis	0.000151	0.000943	CbGpPWpGaD
Naloxone—CREB1—Signaling by SCF-KIT—MMP9—focal segmental glomerulosclerosis	0.000144	0.000904	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000143	0.000897	CbGpPWpGaD
Naloxone—OPRM1—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.000143	0.000893	CbGpPWpGaD
Naloxone—OPRK1—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	0.000142	0.000892	CbGpPWpGaD
Naloxone—ABCB1—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	0.000142	0.000892	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—SERPINE1—focal segmental glomerulosclerosis	0.000142	0.000889	CbGpPWpGaD
Naloxone—ALB—Platelet degranulation—FN1—focal segmental glomerulosclerosis	0.000141	0.000883	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.00014	0.000875	CbGpPWpGaD
Naloxone—ESR1—Regulation of Telomerase—TGFB1—focal segmental glomerulosclerosis	0.00014	0.000875	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000137	0.000857	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—SERPINE1—focal segmental glomerulosclerosis	0.000137	0.000857	CbGpPWpGaD
Naloxone—ESR1—AP-1 transcription factor network—TGFB1—focal segmental glomerulosclerosis	0.000136	0.000855	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000136	0.000854	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000136	0.000852	CbGpPWpGaD
Naloxone—ALB—Hemostasis—ACTN4—focal segmental glomerulosclerosis	0.000135	0.000847	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000135	0.000843	CbGpPWpGaD
Naloxone—ALB—Response to elevated platelet cytosolic Ca2+—FN1—focal segmental glomerulosclerosis	0.000134	0.000841	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000129	0.000809	CbGpPWpGaD
Naloxone—CREB1—Adipogenesis—TGFB1—focal segmental glomerulosclerosis	0.000127	0.000795	CbGpPWpGaD
Naloxone—OPRM1—TCR Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000126	0.000788	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	0.000126	0.000788	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000124	0.00078	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000123	0.000767	CbGpPWpGaD
Naloxone—OPRM1—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	0.00012	0.000754	CbGpPWpGaD
Naloxone—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.00012	0.000751	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000118	0.000742	CbGpPWpGaD
Naloxone—ALB—Platelet degranulation—SERPINE1—focal segmental glomerulosclerosis	0.000117	0.000735	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000115	0.000722	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000115	0.00072	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000113	0.000709	CbGpPWpGaD
Naloxone—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—focal segmental glomerulosclerosis	0.000112	0.0007	CbGpPWpGaD
Naloxone—CREB1—Immune System—MYH9—focal segmental glomerulosclerosis	0.000112	0.000698	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD79A—focal segmental glomerulosclerosis	0.000111	0.000698	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.00011	0.000687	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	0.000109	0.000681	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—CTGF—focal segmental glomerulosclerosis	0.000106	0.000661	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	0.000105	0.000659	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—LPL—focal segmental glomerulosclerosis	0.000105	0.000658	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000104	0.000651	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000104	0.000649	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000103	0.000647	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000103	0.000643	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—MMP2—focal segmental glomerulosclerosis	9.87e-05	0.000618	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	9.83e-05	0.000616	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	9.73e-05	0.00061	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	9.7e-05	0.000608	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	9.57e-05	0.000599	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	9.41e-05	0.000589	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	9.38e-05	0.000587	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	9.35e-05	0.000586	CbGpPWpGaD
Naloxone—SLCO1A2—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	9.33e-05	0.000585	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	9.33e-05	0.000585	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	9.32e-05	0.000584	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	9.08e-05	0.000569	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	9.05e-05	0.000567	CbGpPWpGaD
Naloxone—ALB—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	9.05e-05	0.000567	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	9e-05	0.000564	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	8.94e-05	0.00056	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	8.92e-05	0.000558	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	8.78e-05	0.00055	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	8.63e-05	0.000541	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	8.62e-05	0.00054	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	8.51e-05	0.000533	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	8.22e-05	0.000515	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	8.18e-05	0.000512	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	7.9e-05	0.000495	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	7.86e-05	0.000493	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	7.84e-05	0.000491	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	7.82e-05	0.00049	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	7.65e-05	0.000479	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	7.61e-05	0.000477	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	7.6e-05	0.000476	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	7.57e-05	0.000474	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	7.56e-05	0.000473	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	7.53e-05	0.000472	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—MMP9—focal segmental glomerulosclerosis	7.42e-05	0.000465	CbGpPWpGaD
Naloxone—ALB—Platelet degranulation—TGFB1—focal segmental glomerulosclerosis	7.41e-05	0.000464	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	7.29e-05	0.000456	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	7.24e-05	0.000454	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	7.19e-05	0.000451	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	7.19e-05	0.00045	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	7.17e-05	0.000449	CbGpPWpGaD
Naloxone—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—focal segmental glomerulosclerosis	7.05e-05	0.000442	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—MMP2—focal segmental glomerulosclerosis	7.04e-05	0.000441	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	6.95e-05	0.000435	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	6.92e-05	0.000434	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	6.91e-05	0.000433	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	6.87e-05	0.000431	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD79A—focal segmental glomerulosclerosis	6.76e-05	0.000423	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	6.69e-05	0.000419	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	6.61e-05	0.000414	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	6.61e-05	0.000414	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	6.55e-05	0.000411	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	6.5e-05	0.000407	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TRPC6—focal segmental glomerulosclerosis	6.48e-05	0.000406	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	6.4e-05	0.000401	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	6.37e-05	0.000399	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	6.29e-05	0.000394	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	6.25e-05	0.000392	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	6.12e-05	0.000383	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	6.11e-05	0.000383	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	6.1e-05	0.000382	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	6.08e-05	0.000381	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	6.08e-05	0.000381	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	5.87e-05	0.000368	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	5.86e-05	0.000367	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	5.85e-05	0.000367	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	5.81e-05	0.000364	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	5.61e-05	0.000352	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	5.58e-05	0.00035	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	5.56e-05	0.000348	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	5.56e-05	0.000348	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	5.54e-05	0.000347	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	5.54e-05	0.000347	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	5.53e-05	0.000346	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	5.51e-05	0.000345	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD40LG—focal segmental glomerulosclerosis	5.51e-05	0.000345	CbGpPWpGaD
Naloxone—ALB—Hemostasis—GNAQ—focal segmental glomerulosclerosis	5.42e-05	0.00034	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	5.39e-05	0.000337	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	5.36e-05	0.000335	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	5.33e-05	0.000334	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	5.31e-05	0.000333	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	5.29e-05	0.000332	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	5.2e-05	0.000326	CbGpPWpGaD
Naloxone—CREB1—nephron tubule—focal segmental glomerulosclerosis	5.11e-05	0.197	CbGeAlD
Naloxone—ESR1—Gene Expression—CTGF—focal segmental glomerulosclerosis	5.08e-05	0.000318	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	5.06e-05	0.000317	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	5.05e-05	0.000316	CbGpPWpGaD
Naloxone—CREB1—Disease—LPL—focal segmental glomerulosclerosis	4.99e-05	0.000313	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	4.99e-05	0.000312	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	4.96e-05	0.000311	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	4.95e-05	0.00031	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	4.92e-05	0.000308	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	4.88e-05	0.000306	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	4.87e-05	0.000305	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.86e-05	0.000304	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.83e-05	0.000303	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—SERPINE1—focal segmental glomerulosclerosis	4.81e-05	0.000301	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	4.74e-05	0.000297	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	4.65e-05	0.000291	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	4.63e-05	0.00029	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	4.5e-05	0.000282	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.5e-05	0.000282	CbGpPWpGaD
Naloxone—CREB1—kidney—focal segmental glomerulosclerosis	4.49e-05	0.173	CbGeAlD
Naloxone—OPRK1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	4.42e-05	0.000277	CbGpPWpGaD
Naloxone—CREB1—cortex of kidney—focal segmental glomerulosclerosis	4.37e-05	0.168	CbGeAlD
Naloxone—CREB1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	4.36e-05	0.000273	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	4.25e-05	0.000266	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	4.24e-05	0.000265	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	4.12e-05	0.000258	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.11e-05	0.000257	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.08e-05	0.000256	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	4.06e-05	0.000254	CbGpPWpGaD
Naloxone—CREB1—Disease—NOS2—focal segmental glomerulosclerosis	3.9e-05	0.000244	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	3.74e-05	0.000234	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	3.73e-05	0.000234	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.71e-05	0.000233	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	3.71e-05	0.000233	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.64e-05	0.000228	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.62e-05	0.000227	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.6e-05	0.000226	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.59e-05	0.000225	CbGpPWpGaD
Naloxone—OPRD1—kidney—focal segmental glomerulosclerosis	3.55e-05	0.137	CbGeAlD
Naloxone—CREB1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.49e-05	0.000219	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.48e-05	0.000218	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.43e-05	0.000215	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—LPL—focal segmental glomerulosclerosis	3.38e-05	0.000212	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.31e-05	0.000207	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.3e-05	0.000207	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	3.28e-05	0.000206	CbGpPWpGaD
Naloxone—CREB1—Disease—SERPINE1—focal segmental glomerulosclerosis	3.28e-05	0.000206	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	3.23e-05	0.000203	CbGpPWpGaD
Naloxone—ALB—Hemostasis—FN1—focal segmental glomerulosclerosis	3.22e-05	0.000202	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.19e-05	0.0002	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NOS2—focal segmental glomerulosclerosis	3.18e-05	0.0002	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.18e-05	0.000199	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.15e-05	0.000197	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.14e-05	0.000197	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.05e-05	0.000191	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.04e-05	0.000191	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.99e-05	0.000187	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.98e-05	0.000187	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—AGT—focal segmental glomerulosclerosis	2.89e-05	0.000181	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.89e-05	0.000181	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.78e-05	0.000174	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.76e-05	0.000173	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.75e-05	0.000173	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—LIPC—focal segmental glomerulosclerosis	2.72e-05	0.000171	CbGpPWpGaD
Naloxone—ALB—Metabolism—LIPC—focal segmental glomerulosclerosis	2.71e-05	0.00017	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	2.68e-05	0.000168	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.66e-05	0.000167	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.61e-05	0.000164	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.58e-05	0.000162	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.45e-05	0.000154	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.45e-05	0.000153	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.41e-05	0.000151	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CTGF—focal segmental glomerulosclerosis	2.4e-05	0.00015	CbGpPWpGaD
Naloxone—ALB—Metabolism—CTGF—focal segmental glomerulosclerosis	2.39e-05	0.000149	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	2.37e-05	0.000149	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.36e-05	0.000148	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	2.32e-05	0.000145	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.3e-05	0.000144	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.29e-05	0.000144	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.29e-05	0.000143	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—ALB—focal segmental glomerulosclerosis	2.22e-05	0.000139	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.21e-05	0.000138	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.21e-05	0.000138	CbGpPWpGaD
Naloxone—ALB—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.2e-05	0.000138	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.17e-05	0.000136	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	2.09e-05	0.000131	CbGpPWpGaD
Naloxone—SLCO1A2—kidney—focal segmental glomerulosclerosis	2.08e-05	0.0802	CbGeAlD
Naloxone—CREB1—Disease—TGFB1—focal segmental glomerulosclerosis	2.07e-05	0.00013	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.04e-05	0.000128	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.03e-05	0.000127	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.01e-05	0.000126	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.96e-05	0.000123	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.93e-05	0.000121	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.81e-05	0.000113	CbGpPWpGaD
Naloxone—ESR1—kidney—focal segmental glomerulosclerosis	1.77e-05	0.068	CbGeAlD
Naloxone—CREB1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.76e-05	0.00011	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.76e-05	0.00011	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.7e-05	0.000106	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.69e-05	0.000106	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—LPL—focal segmental glomerulosclerosis	1.66e-05	0.000104	CbGpPWpGaD
Naloxone—ALB—Metabolism—LPL—focal segmental glomerulosclerosis	1.65e-05	0.000104	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.54e-05	9.64e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.51e-05	9.43e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	1.46e-05	9.16e-05	CbGpPWpGaD
Naloxone—CYP2C8—kidney—focal segmental glomerulosclerosis	1.46e-05	0.056	CbGeAlD
Naloxone—CREB1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.45e-05	9.09e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	1.45e-05	9.07e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.45e-05	9.06e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AGT—focal segmental glomerulosclerosis	1.42e-05	8.91e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—AGT—focal segmental glomerulosclerosis	1.41e-05	8.86e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.3e-05	8.15e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	1.29e-05	8.07e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.27e-05	7.95e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	1.24e-05	7.76e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.19e-05	7.43e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.15e-05	7.22e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALB—focal segmental glomerulosclerosis	1.09e-05	6.84e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.07e-05	6.72e-05	CbGpPWpGaD
Naloxone—CYP3A4—kidney—focal segmental glomerulosclerosis	9.86e-06	0.0379	CbGeAlD
Naloxone—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	9.51e-06	5.96e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.51e-06	5.95e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	8.92e-06	5.59e-05	CbGpPWpGaD
Naloxone—ABCB1—nephron tubule—focal segmental glomerulosclerosis	7.94e-06	0.0306	CbGeAlD
Naloxone—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	7.63e-06	4.78e-05	CbGpPWpGaD
Naloxone—ABCB1—kidney—focal segmental glomerulosclerosis	6.98e-06	0.0269	CbGeAlD
Naloxone—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	6.79e-06	0.0262	CbGeAlD
Naloxone—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	5.86e-06	3.67e-05	CbGpPWpGaD
